# A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

NCT06866405

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Phase 3 |
| **Sponsor** | Pfizer |
| **Enrollment** | 550 participants |

## Key Eligibility Criteria

### Inclusion (8)

- Women aged 18 to 49 who are pregnant, between 24 and 36 weeks along, and expecting one baby without known risks for complications can participate.
- Had the RSVpreF or Abrysvo vaccine during a previous pregnancy.
- Had an ultrasound scan at 18 weeks or later during their current pregnancy, with no major fetal problems detected.
- Based on their medical history, physical check-up, and the doctor's judgment, they are found suitable to join the study.
- Agrees to let their baby take part in the study and gives their permission.

... and 3 more (see full listing online)

### Exclusion (11)

- Received any approved or experimental RSV vaccine since their previous pregnancy.
- Has a pre-pregnancy body mass index (BMI) over 40 kg/m2.
- History of a severe bad reaction to a vaccine or a serious allergic reaction (like anaphylaxis) to any ingredient in the study vaccine or a similar vaccine.
- Current pregnancy problems or issues at the time of giving consent.
- Previous pregnancy issues or problems at the time of giving consent.

... and 6 more (see full listing online)

## Locations (93 total)

Center for Research in Women's Health, Birmingham, Alabama, United States
Children's of Alabama, Birmingham, Alabama, United States
University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States
... and 90 more locations



DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.